DCGI

National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines…

The company will be using its stem cell product, Stempeucel, for conducting the label extension phase-III clinical trial

The company, however, is yet to submit the full follow up data of clinical trial of Covaxin to DCGI, a source said.

Bharat Biotech had conducted phase-II/III, open-label and multi-centre studies to evaluate the safety, reactogenicity and…

Serum Institute of India (SII) had sent an application to the DCGI in October for the grant of market authorisation of Covovax for…

According to WHO, Covovax was assessed under its emergency use listing procedure based on the review of data on quality, safety…

In an application to DCGI, Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII, cited that the UK’s MHRA has…

The Serum Institute of India (SII) had put in an application to the Drugs Controller General of India (DCGI) in October for grant…

The company submits first New Drug Application (NDA) to DCGI

Our goal is to enable India as a responsible nutraceutical global hub, while the vision is to catalyse idea to commercialisation…